A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms REGAIN
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Dec 2017 According to an Eli Lilly media release, the US FDA has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults. The BLA submission was based on the results from EVOLVE-1, EVOLVE-2 and REGAIN studies.
    • 11 Sep 2017 Results from this trial presented at the 18th Congress of the International Headache Society 2017, according to The International Headache Society media release.
    • 06 Sep 2017 According to an Eli Lilly media release, data from this study will be presented at the 18th Congress of the International Headache Society (IHC) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top